# Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker - Phase III Non CTIMP Trial

> **NCT02704520** · NA · RECRUITING · sponsor: **Imperial College London** · enrollment: 441 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **DIAGNOSTIC_TEST:** High resolution MRI scan
- **DIAGNOSTIC_TEST:** mrTRG assessment

## Key facts

- **NCT ID:** NCT02704520
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2016-03
- **Primary completion:** 2026-12
- **Final completion:** 2036-12
- **Target enrollment:** 441 (ESTIMATED)
- **Last updated:** 2024-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02704520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02704520, "Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker - Phase III Non CTIMP Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02704520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*